AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00613626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo oral daily
Trial: NCT00613626
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD6474 100mg oral daily to be continued for the duration of the study.
Trial: NCT02624648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They will receive a capsule of Placebo twice a day for 120 days
Trial: NCT00324103
Drug: Structured Treatment Interruptions
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01097902
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg oral one time only
Trial: NCT01097902
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet oral one time only
Trial: NCT00213239
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
Trial: NCT00213239
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
Trial: NCT04472689
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation
Trial: NCT00877838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules resembling the ones containing the active substance
Trial: NCT00866437
Drug: Skin test panel
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Trial: NCT00866437
Drug: Skin test panel
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1 mmol/L~3. Estrone 3 mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Trial: NCT03959189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT02101008
Drug: disulfiram and chelated zinc
RxNorm normalized name: zinc, chelated
DrugBank: Zinc (DB01593)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00470821
Drug: Oral melatonin 3mg BID
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
Trial: NCT00470821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
Trial: NCT02013323
Drug: Scaling and root planing, and Septilin for 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
Trial: NCT02013323
Drug: Scaling and root planing, and Placebo drug for 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
Trial: NCT00001303
Drug: Reference Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001303
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04321343
Drug: PXL065
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXL065 oral tablet
Trial: NCT04321343
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT00590161
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tid
Trial: NCT03981601
Drug: Lovastatin 40 MG
RxNorm normalized name: lovastatin 40 MG
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
Trial: NCT01261403
Drug: Vehicle Controlled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7
Trial: NCT01653301
Drug: XELAC RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost).
Trial: NCT02332486
Drug: Qingxuan Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
Trial: NCT00256789
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01653301
Drug: XELOX RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~* Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost).
Trial: NCT01960010
Drug: MIM-D3 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% MIM-D3 dosed BID
Trial: NCT01960010
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle dosed BID
Trial: NCT02871479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo cream containing the same components as the vehicle for the active intervention arm
Trial: NCT02006576
Drug: 600 mg ibuprofen three times daily for 48 weeks
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01151137
Drug: Placebo (for Dronedarone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)
Trial: NCT01097044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
Trial: NCT00785577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks
Trial: NCT00785577
Drug: LY545694 49 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks.
Trial: NCT00785577
Drug: LY545694 105 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks
Trial: NCT00025038
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01212445
Drug: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
Trial: NCT03542994
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01381081
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single betamethasone and bupivacaine intra-articular injection
Trial: NCT03551522
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo Capsule
Trial: NCT00030082
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00601978
Drug: carbidopa/levodopa
RxNorm normalized name: CARBIDOPA/LEVODOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00601978
Drug: Carbidopa/Levodopa/Entacapone
RxNorm normalized name: carbidopa/levodopa/entacapone 25 mg-100 mg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02451956
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
Trial: NCT03217162
Drug: surfactant combined with mechanical ventilation (MV)
RxNorm normalized name: surfactant protein-D homotrimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
Trial: NCT03887936
Drug: Testosterone gel 1.62%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.
Trial: NCT03887936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo gel, apply 2 pumps to upper arm and shoulder
Trial: NCT02427165
Drug: RPL554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dual PDE3 and PDE4 inhibitor
Trial: NCT02427165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPL554 placebo containing no active ingredients
Trial: NCT01121289
Drug: NN1218
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Trial: NCT01771783
Drug: ACEI-ARB-RI
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01771783
Drug: ARB-RI-ACEI
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01771783
Drug: RI-ACEI-ARB
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01510899
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of RO4917838
Trial: NCT00779129
Drug: Pegylated Lyposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Trial: NCT00779129
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Trial: NCT02293109
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02293109
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02293109
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02293109
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT02462161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will administer placebo two times per day with an intranasal delivery device.
Trial: NCT03263091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT00135421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
Trial: NCT04101812
Drug: pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
Trial: NCT00537719
Drug: GSK716155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albiglutide subcutaneous injection
Trial: NCT00537719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection
Trial: NCT01896232
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once a day.
Trial: NCT01896232
Drug: Intravenous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) three times per week.
Trial: NCT01662089
Drug: 15 mg Chelate zinc supplement
RxNorm normalized name: Zinc, chelated
DrugBank: Zinc (DB01593)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg Chelate zinc additional to standard 5% minoxidil
Trial: NCT01662089
Drug: Placebo drug supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug instead of Zinc supplement
Trial: NCT01381094
Drug: AKB-6548
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose administered once daily for 42 days
Trial: NCT01381094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral Placebo administered once daily for 42 days
Trial: NCT03061708
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mTOR inhibitor
Trial: NCT02443402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill daily until discharge
Trial: NCT02443402
Drug: Regular Human Insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous insulin given to ICU patients with a BG \> 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
Trial: NCT01737814
Drug: MST-188
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00277537
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BD for 12 weeks
Trial: NCT02314806
Drug: Irrigation with gentamicin solution
RxNorm normalized name: gentamicin Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The surgical bed is irrigated with a gentamicin solution
Trial: NCT02314806
Drug: Irrigation with Clindamycin solution
RxNorm normalized name: clindamycin Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The surgical bed is irrigated with a clindamycin solution
Trial: NCT03033199
Drug: Probiotic Agent
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
Trial: NCT01707381
Drug: BOL-303259-X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic solution
Trial: NCT04721873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, titrated as active intervention
Trial: NCT00864760
Drug: NEURONTIN® 400 mg capsules, single dose (2 capsules)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
Trial: NCT00418288
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of 1.2pmol/kg/min
Trial: NCT04178590
Drug: SRP + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline application during scaling and root planing
Trial: NCT01585129
Drug: Postpartum Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
Trial: NCT02432807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01324830
Drug: day 1 to day 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low to high dose
Trial: NCT03360929
Drug: AZD3759
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
Trial: NCT00251602
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-time 0.25 ml/min infusion over 30 minutes
Trial: NCT00003029
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03492164
Drug: [18F]FluorThanatrace ([18F]FTT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
Trial: NCT01477021
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00391976
Drug: Tobramycin solution for inhalation 300 mg
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
Trial: NCT00889356
Drug: Clindamycin 100mg and Ketoconazole 400mg
RxNorm normalized name: clindamycin 100 MG
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 vaginal capsule once a day at night
Trial: NCT00889356
Drug: Tetracycline 100mg and Amphotericin B 50mg
RxNorm normalized name: amphotericin B / tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One full applicator, once a day at night
Trial: NCT02724033
Drug: Antiemetic
RxNorm normalized name: ANTIEMETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiemetic
Trial: NCT03115424
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
Trial: NCT02278601
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
Trial: NCT02582905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredient matching the active comparators in appearance.
Trial: NCT01223664
Drug: Conserved therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or intravenous administration
Trial: NCT00485108
Drug: prednisolone 1%
RxNorm normalized name: GENTAMICIN 0.3/PREDNISOLONE 1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drop once in each eye treated, 4 times / day for 5 days post-laser
Trial: NCT00485108
Drug: ketorolac 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drop once in each eye treated, 4 times / day for 5 days post-laser
Trial: NCT00677339
Drug: Placebo L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo L-arginine once daily
Trial: NCT04028388
Drug: ModraDoc006/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets